1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Opsens Inc.
  6. News
  7. Summary
    OPS   CA6838231083

OPSENS INC.

(OPS)
  Report
Delayed Toronto Stock Exchange  -  03:52 2022-06-24 pm EDT
2.090 CAD   +0.48%
06/07Opsens Details Global SavvyWire First Commercial Use
MT
06/07OPSENS ANNOUNCES GLOBAL SAVVYWIRE™ FIRST COMMERCIAL USE
AQ
05/19Opsens Presents Results of First-in-human Study of SavvyWire at European Conf
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Opsens Presents Results of First-in-human Study of SavvyWire at European Conf

05/19/2022 | 09:10am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
EDWARDS LIFESCIENCES CORPORATION 3.59% 96.98 Delayed Quote.-25.14%
MEDTRONIC PLC 1.75% 90.22 Delayed Quote.-12.79%
OPSENS INC. 0.48% 2.09 Delayed Quote.-32.58%
All news about OPSENS INC.
06/07Opsens Details Global SavvyWire First Commercial Use
MT
06/07OPSENS ANNOUNCES GLOBAL SAVVYWIRE™ FIRST COMMERCIAL USE
AQ
05/19Opsens Presents Results of First-in-human Study of SavvyWire at European Conf
MT
05/19OPSENS SAVVYWIRE™ FIRST-IN-HUMAN RESULTS PRESENTED AT EUROPCR IN PARIS AND SIMULT..
AQ
05/19Opsens Inc. Announces New Data Supporting the Safety and Efficacy of its SavvyWire Rece..
CI
05/18Opsens Announces Publication of New Optowire Data in Journal
MT
05/18Opsens announces publication in jscai of data supporting the correlation between the op..
AQ
04/26OpSens Announces Health Canada Approval For Its New TAVR Guidewire
MT
04/26Opsens announces health canada approval for its new tavr guidewire
AQ
04/26Opsens Inc. Announces Health Canada Approval for Its New TAVR Guidewire
CI
More news
Analyst Recommendations on OPSENS INC.
More recommendations
Financials
Sales 2022 36,6 M 28,3 M 28,3 M
Net income 2022 -7,29 M -5,65 M -5,65 M
Net Debt 2022 - - -
P/E ratio 2022 -31,0x
Yield 2022 -
Capitalization 227 M 176 M 176 M
Capi. / Sales 2022 6,20x
Capi. / Sales 2023 4,17x
Nbr of Employees 163
Free-Float 95,2%
Chart OPSENS INC.
Duration : Period :
Opsens Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OPSENS INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 2,09 CAD
Average target price 4,22 CAD
Spread / Average Target 102%
EPS Revisions
Managers and Directors
Louis Laflamme President, Chief Executive Officer & Director
Robin Villeneuve Chief Financial Officer & Secretary
Alan W. Milinazzo Executive Chairman
Jean Lavigueur Independent Director
Denis L. Harrington Independent Director
Sector and Competitors